Qing Yuan - Cabaletta Bio Chief Officer
| CABA Stock | USD 3.82 0.81 26.91% |
Executive
Qing Yuan is Chief Officer of Cabaletta Bio
| Age | 53 |
| Address | 2929 Arch Street, Philadelphia, PA, United States, 19104 |
| Phone | 267 759 3100 |
| Web | https://www.cabalettabio.com |
Cabaletta Bio Management Efficiency
The company has return on total asset (ROA) of (0.3113) % which means that it has lost $0.3113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4816) %, meaning that it created substantial loss on money invested by shareholders. Cabaletta Bio's management efficiency ratios could be used to measure how well Cabaletta Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.28. The current year's Return On Capital Employed is expected to grow to -0.3. At present, Cabaletta Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 9.6 M, whereas Net Tangible Assets are forecasted to decline to about 84 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Danielle JD | Alector | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Francis Sarena | 89bio Inc | 53 | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Aileen Fernandes | Arcellx | N/A | |
| Shiva Natarajan | 89bio Inc | 58 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| Mike JD | Pliant Therapeutics | 51 | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Amanda Kurihara | 89bio Inc | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Myesha Lacy | Arcellx | N/A | |
| JD Esq | Passage Bio | 60 | |
| Eric MD | Pliant Therapeutics | 60 | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Yun Bai | 89bio Inc | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.31 |
Cabaletta Bio Leadership Team
Elected by the shareholders, the Cabaletta Bio's board of directors comprises two types of representatives: Cabaletta Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cabaletta. The board's role is to monitor Cabaletta Bio's management team and ensure that shareholders' interests are well served. Cabaletta Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cabaletta Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samik MD, Chief Officer | ||
| Steven MD, Chairman, CoFounder | ||
| FACR MD, Chief Officer | ||
| Michael JD, General Secretary | ||
| Heather MSc, Chief Officer | ||
| Qing Yuan, Chief Officer | ||
| Aimee MD, CoFounder Board | ||
| Gwendolyn Binder, President Technology | ||
| Arun MD, Chief Officer | ||
| Anup MBA, Chief Officer | ||
| Martha OConnor, Chief Officer |
Cabaletta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cabaletta Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 18.92 M | ||||
| Shares Outstanding | 48.88 M | ||||
| Shares Owned By Insiders | 3.09 % | ||||
| Shares Owned By Institutions | 96.91 % | ||||
| Number Of Shares Shorted | 3.6 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 1.07 X | ||||
| EBITDA | (73.23 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cabaletta Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cabaletta Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cabaletta Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cabaletta Bio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Return On Assets (0.31) | Return On Equity (0.48) |
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.